The term VLP Activators refers to a specific category of chemical compounds designed to modulate the activity of Virus-Like Particles (VLPs). VLPs are self-assembling structures composed of viral structural proteins that mimic the organization and appearance of actual viruses but lack the genetic material necessary for replication. They are widely used in molecular virology and vaccine development research. VLPs can be engineered to display specific viral antigens on their surfaces, making them valuable tools for studying viral behavior and eliciting immune responses against targeted pathogens. VLP Activators, in this context, typically consist of small molecules or chemical agents strategically designed to enhance the assembly, stability, or antigen-presenting properties of VLPs.
The mechanism of action for VLP Activators can vary depending on the specific goals of the research. Some compounds may enhance the interaction between viral structural proteins, promoting more efficient VLP assembly. Others may stabilize VLP structures, preventing their disintegration and ensuring their integrity during storage or experimental procedures. Additionally, VLP Activators might influence the surface display of viral antigens on VLPs, making them more immunogenic and capable of eliciting stronger immune responses. Researchers use VLP Activators in virology and vaccinology studies to investigate the behavior and immunogenic properties of VLPs, as well as their potential applications in vaccine development and viral research. By selectively modulating VLP properties, researchers can gain insights into their structural and antigenic characteristics, allowing for the design of more effective vaccines and a better understanding of viral biology. Overall, VLP Activators provide valuable tools for exploring the applications of Virus-Like Particles in various research contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tetracycline | 60-54-8 | sc-205858 sc-205858A sc-205858B sc-205858C sc-205858D | 10 g 25 g 100 g 500 g 1 kg | $63.00 $94.00 $270.00 $417.00 $634.00 | 6 | |
In systems using tetracycline-inducible promoters, tetracycline or its derivatives can activate the expression of viral proteins used to form VLPs. | ||||||
IPTG, Dioxane-Free | 367-93-1 | sc-202185 sc-202185A sc-202185B sc-202185C sc-202185D sc-202185E sc-202185F | 1 g 5 g 100 g 500 g 1 kg 10 kg 25 kg | $51.00 $117.00 $510.00 $1785.00 $2240.00 $16646.00 $32773.00 | 27 | |
IPTG is used to induce the expression of proteins in systems controlled by the lac operon, potentially including viral structural proteins for VLP production. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate can enhance protein production in mammalian cells by inhibiting HDAC, potentially increasing the yield of viral proteins for VLP assembly. | ||||||
Doxycycline-d6 | 564-25-0 unlabeled | sc-218274 | 1 mg | $16500.00 | ||
Doxycycline can be used to induce protein expression in tetracycline-inducible expression systems, potentially including those for VLP production. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone can be used in certain inducible expression systems to enhance the production of target proteins, possibly including viral structural proteins for VLPs. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Mifepristone can be used in inducible gene expression systems to regulate the expression of target proteins, including viral proteins for VLPs. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Hydrocortisone can enhance the expression of proteins in certain mammalian expression systems, potentially applicable to VLP production. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc sulfate can induce metallothionein promoter-based expression systems, potentially useful for expressing viral proteins for VLPs. | ||||||